vs
REGENXBIO Inc.（RGNX）与REDWOOD TRUST INC（RWT）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是REDWOOD TRUST INC的1.2倍（$30.3M vs $25.9M），REDWOOD TRUST INC净利率更高（77.2% vs -221.3%，领先298.6%），REGENXBIO Inc.同比增速更快（43.0% vs -6.1%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -41.0%）
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
Redwood Trust Inc是总部位于美国的专业房地产投资信托公司，主营住宅与商业抵押贷款、抵押贷款支持证券及房地产信贷类资产的投资管理，核心业务覆盖住宅抵押贷款发放、商业地产信贷和投资服务，客户以机构投资者和房地产市场参与者为主。
RGNX vs RWT — 直观对比
营收规模更大
RGNX
是对方的1.2倍
$25.9M
营收增速更快
RGNX
高出49.1%
-6.1%
净利率更高
RWT
高出298.6%
-221.3%
两年增速更快
RGNX
近两年复合增速
-41.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $30.3M | $25.9M |
| 净利润 | $-67.1M | $20.0M |
| 毛利率 | — | — |
| 营业利润率 | -190.0% | — |
| 净利率 | -221.3% | 77.2% |
| 营收同比 | 43.0% | -6.1% |
| 净利润同比 | -31.2% | 402.6% |
| 每股收益（稀释后） | $-1.30 | $0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RGNXRWT
| Q4 25 | $30.3M | $25.9M | ||
| Q3 25 | $29.7M | $15.0M | ||
| Q2 25 | $21.4M | $13.8M | ||
| Q1 25 | $89.0M | $27.9M | ||
| Q4 24 | $21.2M | $27.6M | ||
| Q3 24 | $24.2M | $25.5M | ||
| Q2 24 | $22.3M | $67.4M | ||
| Q1 24 | $15.6M | $74.5M |
净利润RGNXRWT
| Q4 25 | $-67.1M | $20.0M | ||
| Q3 25 | $-61.9M | $-7.7M | ||
| Q2 25 | $-70.9M | $-98.5M | ||
| Q1 25 | $6.1M | $16.1M | ||
| Q4 24 | $-51.2M | $-6.6M | ||
| Q3 24 | $-59.6M | $14.8M | ||
| Q2 24 | $-53.0M | $15.5M | ||
| Q1 24 | $-63.3M | $30.3M |
毛利率RGNXRWT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 70.2% | — | ||
| Q3 24 | 48.8% | — | ||
| Q2 24 | 52.5% | — | ||
| Q1 24 | 72.6% | — |
营业利润率RGNXRWT
| Q4 25 | -190.0% | — | ||
| Q3 25 | -176.3% | -9.0% | ||
| Q2 25 | -296.3% | -679.0% | ||
| Q1 25 | 13.6% | 80.2% | ||
| Q4 24 | -242.1% | -1.3% | ||
| Q3 24 | -256.6% | 86.1% | ||
| Q2 24 | -251.3% | 30.3% | ||
| Q1 24 | -408.8% | 41.3% |
净利率RGNXRWT
| Q4 25 | -221.3% | 77.2% | ||
| Q3 25 | -208.3% | -51.4% | ||
| Q2 25 | -331.8% | -712.0% | ||
| Q1 25 | 6.8% | 57.8% | ||
| Q4 24 | -241.3% | -24.0% | ||
| Q3 24 | -246.3% | 58.1% | ||
| Q2 24 | -237.7% | 23.0% | ||
| Q1 24 | -405.4% | 40.6% |
每股收益（稀释后）RGNXRWT
| Q4 25 | $-1.30 | $0.11 | ||
| Q3 25 | $-1.20 | $-0.08 | ||
| Q2 25 | $-1.38 | $-0.76 | ||
| Q1 25 | $0.12 | $0.10 | ||
| Q4 24 | $-0.99 | $-0.08 | ||
| Q3 24 | $-1.17 | $0.09 | ||
| Q2 24 | $-1.05 | $0.10 | ||
| Q1 24 | $-1.38 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $230.1M | $255.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $102.7M | $982.6M |
| 总资产 | $453.0M | $23.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资RGNXRWT
| Q4 25 | $230.1M | $255.7M | ||
| Q3 25 | $274.2M | $226.3M | ||
| Q2 25 | $323.3M | $302.0M | ||
| Q1 25 | $267.9M | $259.9M | ||
| Q4 24 | $234.7M | $245.2M | ||
| Q3 24 | $255.5M | $253.7M | ||
| Q2 24 | $290.4M | $275.6M | ||
| Q1 24 | $338.7M | $275.4M |
总债务RGNXRWT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $1.7B |
股东权益RGNXRWT
| Q4 25 | $102.7M | $982.6M | ||
| Q3 25 | $161.5M | $999.0M | ||
| Q2 25 | $213.7M | $1.1B | ||
| Q1 25 | $274.2M | $1.2B | ||
| Q4 24 | $259.7M | $1.2B | ||
| Q3 24 | $301.4M | $1.2B | ||
| Q2 24 | $348.3M | $1.2B | ||
| Q1 24 | $390.7M | $1.2B |
总资产RGNXRWT
| Q4 25 | $453.0M | $23.7B | ||
| Q3 25 | $525.2M | $22.6B | ||
| Q2 25 | $581.0M | $21.3B | ||
| Q1 25 | $490.9M | $19.9B | ||
| Q4 24 | $466.0M | $18.3B | ||
| Q3 24 | $519.1M | $18.4B | ||
| Q2 24 | $569.4M | $16.5B | ||
| Q1 24 | $629.2M | $15.1B |
负债/权益比RGNXRWT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.39× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-52.3M | $-10.1B |
| 自由现金流经营现金流 - 资本支出 | $-52.8M | — |
| 自由现金流率自由现金流/营收 | -174.0% | — |
| 资本支出强度资本支出/营收 | 1.7% | — |
| 现金转化率经营现金流/净利润 | — | -504.15× |
| 过去12个月自由现金流最近4个季度 | $-126.4M | — |
8季度趋势，按日历期对齐
经营现金流RGNXRWT
| Q4 25 | $-52.3M | $-10.1B | ||
| Q3 25 | $-56.0M | $-2.7B | ||
| Q2 25 | $-49.3M | $-2.1B | ||
| Q1 25 | $33.6M | $-2.0B | ||
| Q4 24 | $-31.6M | $-5.9B | ||
| Q3 24 | $-40.5M | $-2.1B | ||
| Q2 24 | $-45.5M | $-2.0B | ||
| Q1 24 | $-55.5M | $-954.2M |
自由现金流RGNXRWT
| Q4 25 | $-52.8M | — | ||
| Q3 25 | $-56.5M | — | ||
| Q2 25 | $-49.7M | — | ||
| Q1 25 | $32.6M | — | ||
| Q4 24 | $-32.7M | — | ||
| Q3 24 | $-40.9M | — | ||
| Q2 24 | $-46.0M | — | ||
| Q1 24 | $-56.0M | — |
自由现金流率RGNXRWT
| Q4 25 | -174.0% | — | ||
| Q3 25 | -189.9% | — | ||
| Q2 25 | -232.8% | — | ||
| Q1 25 | 36.6% | — | ||
| Q4 24 | -154.2% | — | ||
| Q3 24 | -168.9% | — | ||
| Q2 24 | -206.2% | — | ||
| Q1 24 | -358.5% | — |
资本支出强度RGNXRWT
| Q4 25 | 1.7% | — | ||
| Q3 25 | 1.7% | — | ||
| Q2 25 | 1.8% | — | ||
| Q1 25 | 1.2% | — | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 1.3% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | 3.6% | — |
现金转化率RGNXRWT
| Q4 25 | — | -504.15× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 5.53× | -120.92× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -140.86× | ||
| Q2 24 | — | -126.56× | ||
| Q1 24 | — | -31.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
RWT
暂无分部数据
